nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—Gefitinib—Lapatinib—breast cancer	0.279	1	CrCrCtD
Erlotinib—ABL1—breast cancer	0.064	0.256	CbGaD
Erlotinib—EGFR—Lapatinib—breast cancer	0.0495	0.186	CbGbCtD
Erlotinib—CYP1B1—breast cancer	0.0413	0.165	CbGaD
Erlotinib—EGFR—breast cancer	0.0389	0.156	CbGaD
Erlotinib—ABCG2—breast cancer	0.0285	0.114	CbGaD
Erlotinib—CYP1A1—breast cancer	0.0223	0.0891	CbGaD
Erlotinib—NR1I2—Paclitaxel—breast cancer	0.0175	0.0659	CbGbCtD
Erlotinib—CYP2D6—breast cancer	0.0166	0.0663	CbGaD
Erlotinib—CYP3A4—breast cancer	0.0142	0.0569	CbGaD
Erlotinib—EGFR—Docetaxel—breast cancer	0.0139	0.0523	CbGbCtD
Erlotinib—NR1I2—Docetaxel—breast cancer	0.0127	0.0476	CbGbCtD
Erlotinib—ALB—breast cancer	0.0124	0.0496	CbGaD
Erlotinib—ABCB1—breast cancer	0.0118	0.0474	CbGaD
Erlotinib—CYP1A1—Toremifene—breast cancer	0.0103	0.0388	CbGbCtD
Erlotinib—CYP1B1—Tamoxifen—breast cancer	0.0086	0.0323	CbGbCtD
Erlotinib—CYP1B1—Mitoxantrone—breast cancer	0.00839	0.0315	CbGbCtD
Erlotinib—CYP1B1—Paclitaxel—breast cancer	0.0067	0.0251	CbGbCtD
Erlotinib—UGT1A1—Irinotecan—breast cancer	0.00571	0.0214	CbGbCtD
Erlotinib—CYP1A2—Anastrozole—breast cancer	0.00505	0.019	CbGbCtD
Erlotinib—CYP1B1—Docetaxel—breast cancer	0.00484	0.0182	CbGbCtD
Erlotinib—CYP1A2—Toremifene—breast cancer	0.00462	0.0173	CbGbCtD
Erlotinib—CYP3A5—Lapatinib—breast cancer	0.00452	0.017	CbGbCtD
Erlotinib—CYP2C8—Lapatinib—breast cancer	0.00435	0.0163	CbGbCtD
Erlotinib—ABCG2—Tamoxifen—breast cancer	0.00409	0.0154	CbGbCtD
Erlotinib—ABCB1—Toremifene—breast cancer	0.00404	0.0152	CbGbCtD
Erlotinib—ABCG2—Mitoxantrone—breast cancer	0.00399	0.015	CbGbCtD
Erlotinib—CYP1A1—Tamoxifen—breast cancer	0.00377	0.0142	CbGbCtD
Erlotinib—CYP1B1—Doxorubicin—breast cancer	0.00361	0.0136	CbGbCtD
Erlotinib—CYP3A4—Exemestane—breast cancer	0.00349	0.0131	CbGbCtD
Erlotinib—CYP2C8—Raloxifene—breast cancer	0.0033	0.0124	CbGbCtD
Erlotinib—ABCG2—Paclitaxel—breast cancer	0.00318	0.012	CbGbCtD
Erlotinib—CYP2D6—Idarubicin—breast cancer	0.00315	0.0118	CbGbCtD
Erlotinib—ABCG2—Irinotecan—breast cancer	0.00314	0.0118	CbGbCtD
Erlotinib—ABCG2—Fluorouracil—breast cancer	0.00301	0.0113	CbGbCtD
Erlotinib—ABCG2—Carboplatin—breast cancer	0.003	0.0112	CbGbCtD
Erlotinib—CYP3A4—Letrozole—breast cancer	0.00297	0.0111	CbGbCtD
Erlotinib—ABCB1—Lapatinib—breast cancer	0.00294	0.0111	CbGbCtD
Erlotinib—CYP3A4—Anastrozole—breast cancer	0.00264	0.00993	CbGbCtD
Erlotinib—CYP3A4—Toremifene—breast cancer	0.00242	0.00908	CbGbCtD
Erlotinib—ABCG2—Docetaxel—breast cancer	0.0023	0.00864	CbGbCtD
Erlotinib—CYP3A5—Tamoxifen—breast cancer	0.00227	0.00851	CbGbCtD
Erlotinib—CYP3A4—Fulvestrant—breast cancer	0.00225	0.00844	CbGbCtD
Erlotinib—CYP2C8—Tamoxifen—breast cancer	0.00218	0.00818	CbGbCtD
Erlotinib—ALB—Irinotecan—breast cancer	0.00216	0.00813	CbGbCtD
Erlotinib—ALB—Fluorouracil—breast cancer	0.00208	0.0078	CbGbCtD
Erlotinib—CYP3A4—Thiotepa—breast cancer	0.002	0.00753	CbGbCtD
Erlotinib—CYP3A4—Ixabepilone—breast cancer	0.00183	0.00688	CbGbCtD
Erlotinib—CYP3A4—Lapatinib—breast cancer	0.00176	0.00663	CbGbCtD
Erlotinib—CYP3A5—Paclitaxel—breast cancer	0.00176	0.00662	CbGbCtD
Erlotinib—CYP3A5—Irinotecan—breast cancer	0.00174	0.00653	CbGbCtD
Erlotinib—ABCG2—Doxorubicin—breast cancer	0.00172	0.00644	CbGbCtD
Erlotinib—CYP2C8—Paclitaxel—breast cancer	0.0017	0.00637	CbGbCtD
Erlotinib—CYP1A2—Tamoxifen—breast cancer	0.00169	0.00633	CbGbCtD
Erlotinib—ABCG2—Methotrexate—breast cancer	0.00166	0.00624	CbGbCtD
Erlotinib—ABCB1—Vinorelbine—breast cancer	0.00163	0.00613	CbGbCtD
Erlotinib—CYP2C8—Fluorouracil—breast cancer	0.00161	0.00603	CbGbCtD
Erlotinib—CYP2D6—Vinorelbine—breast cancer	0.00154	0.00578	CbGbCtD
Erlotinib—ABCB1—Tamoxifen—breast cancer	0.00147	0.00554	CbGbCtD
Erlotinib—ABCB1—Mitoxantrone—breast cancer	0.00144	0.0054	CbGbCtD
Erlotinib—CYP2D6—Tamoxifen—breast cancer	0.00139	0.00522	CbGbCtD
Erlotinib—CYP3A4—Raloxifene—breast cancer	0.00134	0.00502	CbGbCtD
Erlotinib—CYP3A5—Docetaxel—breast cancer	0.00127	0.00479	CbGbCtD
Erlotinib—ABCB1—Gemcitabine—breast cancer	0.00127	0.00477	CbGbCtD
Erlotinib—CYP1A2—Fluorouracil—breast cancer	0.00124	0.00467	CbGbCtD
Erlotinib—ABCB1—Paclitaxel—breast cancer	0.00115	0.00431	CbGbCtD
Erlotinib—ALB—Methotrexate—breast cancer	0.00115	0.0043	CbGbCtD
Erlotinib—ABCB1—Irinotecan—breast cancer	0.00113	0.00425	CbGbCtD
Erlotinib—ABCB1—Vinblastine—breast cancer	0.00101	0.00378	CbGbCtD
Erlotinib—CYP3A4—Vinorelbine—breast cancer	0.000979	0.00368	CbGbCtD
Erlotinib—CYP2D6—Vinblastine—breast cancer	0.000948	0.00356	CbGbCtD
Erlotinib—CYP3A4—Tamoxifen—breast cancer	0.000883	0.00332	CbGbCtD
Erlotinib—CYP3A4—Mitoxantrone—breast cancer	0.000862	0.00324	CbGbCtD
Erlotinib—ABCB1—Docetaxel—breast cancer	0.00083	0.00312	CbGbCtD
Erlotinib—CYP3A4—Paclitaxel—breast cancer	0.000688	0.00258	CbGbCtD
Erlotinib—CYP3A4—Irinotecan—breast cancer	0.000678	0.00255	CbGbCtD
Erlotinib—TNK1—nipple—breast cancer	0.000634	0.0174	CbGeAlD
Erlotinib—ABCB1—Doxorubicin—breast cancer	0.000618	0.00232	CbGbCtD
Erlotinib—EGFR—mammary gland—breast cancer	0.000614	0.0169	CbGeAlD
Erlotinib—CYP3A4—Vinblastine—breast cancer	0.000603	0.00226	CbGbCtD
Erlotinib—ABCB1—Methotrexate—breast cancer	0.000599	0.00225	CbGbCtD
Erlotinib—PIP4K2C—mammary gland—breast cancer	0.000595	0.0164	CbGeAlD
Erlotinib—MKNK1—Estradiol—Fulvestrant—breast cancer	0.000591	0.394	CbGdCrCtD
Erlotinib—CYP2D6—Doxorubicin—breast cancer	0.000583	0.00219	CbGbCtD
Erlotinib—MKNK1—mammary gland—breast cancer	0.000535	0.0147	CbGeAlD
Erlotinib—SLK—mammary gland—breast cancer	0.000507	0.0139	CbGeAlD
Erlotinib—CYP3A4—Docetaxel—breast cancer	0.000497	0.00187	CbGbCtD
Erlotinib—PIP4K2C—nipple—breast cancer	0.000492	0.0135	CbGeAlD
Erlotinib—ULK3—nipple—breast cancer	0.00047	0.0129	CbGeAlD
Erlotinib—MKNK1—nipple—breast cancer	0.000442	0.0122	CbGeAlD
Erlotinib—HIPK4—female reproductive system—breast cancer	0.000437	0.012	CbGeAlD
Erlotinib—LTK—female reproductive system—breast cancer	0.000432	0.0119	CbGeAlD
Erlotinib—SLK—nipple—breast cancer	0.000419	0.0115	CbGeAlD
Erlotinib—TNK1—endometrium—breast cancer	0.000383	0.0105	CbGeAlD
Erlotinib—JAK3—adipose tissue—breast cancer	0.000376	0.0103	CbGeAlD
Erlotinib—AURKC—female reproductive system—breast cancer	0.000373	0.0103	CbGeAlD
Erlotinib—CYP3A4—Doxorubicin—breast cancer	0.000371	0.00139	CbGbCtD
Erlotinib—HIPK4—endocrine gland—breast cancer	0.00037	0.0102	CbGeAlD
Erlotinib—NR1I2—endocrine gland—breast cancer	0.000366	0.0101	CbGeAlD
Erlotinib—AURKC—adrenal gland—breast cancer	0.000364	0.01	CbGeAlD
Erlotinib—TNK1—uterus—breast cancer	0.000353	0.00971	CbGeAlD
Erlotinib—TNK1—pituitary gland—breast cancer	0.000347	0.00953	CbGeAlD
Erlotinib—JAK3—female reproductive system—breast cancer	0.000346	0.0095	CbGeAlD
Erlotinib—EPHA6—female reproductive system—breast cancer	0.000346	0.0095	CbGeAlD
Erlotinib—JAK3—adrenal gland—breast cancer	0.000337	0.00927	CbGeAlD
Erlotinib—MAP2K5—nipple—breast cancer	0.000325	0.00895	CbGeAlD
Erlotinib—AURKC—endocrine gland—breast cancer	0.000316	0.00868	CbGeAlD
Erlotinib—JAK3—female gonad—breast cancer	0.000314	0.00865	CbGeAlD
Erlotinib—MAP3K19—female reproductive system—breast cancer	0.000314	0.00864	CbGeAlD
Erlotinib—TNK1—adrenal gland—breast cancer	0.00031	0.00851	CbGeAlD
Erlotinib—SLCO2B1—mammary gland—breast cancer	0.000306	0.00842	CbGeAlD
Erlotinib—ABL1—mammary gland—breast cancer	0.000303	0.00834	CbGeAlD
Erlotinib—PIP4K2C—endometrium—breast cancer	0.000297	0.00817	CbGeAlD
Erlotinib—JAK3—endocrine gland—breast cancer	0.000292	0.00804	CbGeAlD
Erlotinib—EPHA6—endocrine gland—breast cancer	0.000292	0.00804	CbGeAlD
Erlotinib—Gefitinib—CHEK2—breast cancer	0.000292	0.12	CrCbGaD
Erlotinib—TNK1—female gonad—breast cancer	0.000289	0.00794	CbGeAlD
Erlotinib—ABL2—pituitary gland—breast cancer	0.000284	0.00782	CbGeAlD
Erlotinib—ULK3—endometrium—breast cancer	0.000284	0.0078	CbGeAlD
Erlotinib—ABL2—adipose tissue—breast cancer	0.000283	0.00779	CbGeAlD
Erlotinib—EGFR—uterus—breast cancer	0.000283	0.00777	CbGeAlD
Erlotinib—ALB—mammary gland—breast cancer	0.00028	0.0077	CbGeAlD
Erlotinib—EGFR—adipose tissue—breast cancer	0.000276	0.0076	CbGeAlD
Erlotinib—Vandetanib—ERBB3—breast cancer	0.000274	0.113	CrCbGaD
Erlotinib—FLT3—female reproductive system—breast cancer	0.000273	0.0075	CbGeAlD
Erlotinib—PIP4K2C—pituitary gland—breast cancer	0.000269	0.0074	CbGeAlD
Erlotinib—TNK1—endocrine gland—breast cancer	0.000268	0.00738	CbGeAlD
Erlotinib—PIP4K2C—adipose tissue—breast cancer	0.000268	0.00737	CbGeAlD
Erlotinib—MKNK1—endometrium—breast cancer	0.000267	0.00735	CbGeAlD
Erlotinib—FLT3—adrenal gland—breast cancer	0.000266	0.00732	CbGeAlD
Erlotinib—ULK3—uterus—breast cancer	0.000262	0.00719	CbGeAlD
Erlotinib—Gefitinib—ERBB3—breast cancer	0.00026	0.107	CrCbGaD
Erlotinib—FLT3—bone marrow—breast cancer	0.000257	0.00708	CbGeAlD
Erlotinib—CYP1B1—mammary gland—breast cancer	0.000257	0.00707	CbGeAlD
Erlotinib—ULK3—pituitary gland—breast cancer	0.000257	0.00706	CbGeAlD
Erlotinib—ULK3—adipose tissue—breast cancer	0.000256	0.00703	CbGeAlD
Erlotinib—ABL2—adrenal gland—breast cancer	0.000254	0.00698	CbGeAlD
Erlotinib—SLK—endometrium—breast cancer	0.000253	0.00696	CbGeAlD
Erlotinib—LTK—lymph node—breast cancer	0.000253	0.00695	CbGeAlD
Erlotinib—ABL1—nipple—breast cancer	0.000251	0.0069	CbGeAlD
Erlotinib—FLT3—female gonad—breast cancer	0.000248	0.00682	CbGeAlD
Erlotinib—EGFR—adrenal gland—breast cancer	0.000248	0.00682	CbGeAlD
Erlotinib—PIP4K2C—female reproductive system—breast cancer	0.000246	0.00677	CbGeAlD
Erlotinib—MKNK1—pituitary gland—breast cancer	0.000242	0.00665	CbGeAlD
Erlotinib—MKNK1—adipose tissue—breast cancer	0.000241	0.00662	CbGeAlD
Erlotinib—PIP4K2C—adrenal gland—breast cancer	0.00024	0.00661	CbGeAlD
Erlotinib—ABL2—female gonad—breast cancer	0.000237	0.00651	CbGeAlD
Erlotinib—ULK3—female reproductive system—breast cancer	0.000235	0.00647	CbGeAlD
Erlotinib—ABL1—Topotecan—Irinotecan—breast cancer	0.000234	0.156	CbGdCrCtD
Erlotinib—SLK—uterus—breast cancer	0.000233	0.00641	CbGeAlD
Erlotinib—PIP4K2C—bone marrow—breast cancer	0.000232	0.00639	CbGeAlD
Erlotinib—EGFR—female gonad—breast cancer	0.000231	0.00636	CbGeAlD
Erlotinib—FLT3—endocrine gland—breast cancer	0.000231	0.00634	CbGeAlD
Erlotinib—ULK3—adrenal gland—breast cancer	0.000229	0.00631	CbGeAlD
Erlotinib—SLK—pituitary gland—breast cancer	0.000229	0.0063	CbGeAlD
Erlotinib—SLK—adipose tissue—breast cancer	0.000228	0.00627	CbGeAlD
Erlotinib—PIP4K2C—female gonad—breast cancer	0.000224	0.00616	CbGeAlD
Erlotinib—ULK3—bone marrow—breast cancer	0.000222	0.0061	CbGeAlD
Erlotinib—MKNK1—female reproductive system—breast cancer	0.000221	0.00609	CbGeAlD
Erlotinib—AURKC—lymph node—breast cancer	0.000218	0.006	CbGeAlD
Erlotinib—MKNK1—adrenal gland—breast cancer	0.000216	0.00594	CbGeAlD
Erlotinib—ULK3—female gonad—breast cancer	0.000214	0.00588	CbGeAlD
Erlotinib—MKNK1—bone marrow—breast cancer	0.000209	0.00574	CbGeAlD
Erlotinib—PIP4K2C—endocrine gland—breast cancer	0.000208	0.00573	CbGeAlD
Erlotinib—ABL1—embryo—breast cancer	0.000207	0.0057	CbGeAlD
Erlotinib—SLK—adrenal gland—breast cancer	0.000205	0.00562	CbGeAlD
Erlotinib—STK10—uterus—breast cancer	0.000203	0.00557	CbGeAlD
Erlotinib—JAK3—lymph node—breast cancer	0.000202	0.00556	CbGeAlD
Erlotinib—Vandetanib—ABL1—breast cancer	0.000202	0.0832	CrCbGaD
Erlotinib—MKNK1—female gonad—breast cancer	0.000201	0.00554	CbGeAlD
Erlotinib—ULK3—endocrine gland—breast cancer	0.000199	0.00547	CbGeAlD
Erlotinib—STK10—adipose tissue—breast cancer	0.000198	0.00545	CbGeAlD
Erlotinib—SLK—bone marrow—breast cancer	0.000198	0.00544	CbGeAlD
Erlotinib—CYP2C8—mammary gland—breast cancer	0.000197	0.00541	CbGeAlD
Erlotinib—MAP2K5—endometrium—breast cancer	0.000196	0.0054	CbGeAlD
Erlotinib—SLK—female gonad—breast cancer	0.000191	0.00524	CbGeAlD
Erlotinib—MKNK1—endocrine gland—breast cancer	0.000187	0.00515	CbGeAlD
Erlotinib—TNK1—lymph node—breast cancer	0.000186	0.0051	CbGeAlD
Erlotinib—Vandetanib—SRC—breast cancer	0.000183	0.0753	CrCbGaD
Erlotinib—STK10—female reproductive system—breast cancer	0.000182	0.00501	CbGeAlD
Erlotinib—STK10—adrenal gland—breast cancer	0.000178	0.00489	CbGeAlD
Erlotinib—MAP2K5—pituitary gland—breast cancer	0.000178	0.00489	CbGeAlD
Erlotinib—MAP2K5—adipose tissue—breast cancer	0.000177	0.00487	CbGeAlD
Erlotinib—STK10—bone marrow—breast cancer	0.000172	0.00473	CbGeAlD
Erlotinib—Vandetanib—KDR—breast cancer	0.000171	0.0707	CrCbGaD
Erlotinib—Vandetanib—ABCC1—breast cancer	0.00017	0.0701	CrCbGaD
Erlotinib—STK10—female gonad—breast cancer	0.000166	0.00456	CbGeAlD
Erlotinib—MAP2K5—female reproductive system—breast cancer	0.000163	0.00448	CbGeAlD
Erlotinib—ABL1—skin of body—breast cancer	0.000161	0.00442	CbGeAlD
Erlotinib—ORM1—endometrium—breast cancer	0.000159	0.00439	CbGeAlD
Erlotinib—FLT3—lymph node—breast cancer	0.000159	0.00439	CbGeAlD
Erlotinib—MAP2K5—adrenal gland—breast cancer	0.000159	0.00437	CbGeAlD
Erlotinib—STK10—endocrine gland—breast cancer	0.000154	0.00424	CbGeAlD
Erlotinib—CYP1A2—nipple—breast cancer	0.000152	0.00419	CbGeAlD
Erlotinib—ABL2—lymph node—breast cancer	0.000152	0.00419	CbGeAlD
Erlotinib—ABL1—endometrium—breast cancer	0.000152	0.00417	CbGeAlD
Erlotinib—CYP1A1—nipple—breast cancer	0.00015	0.00413	CbGeAlD
Erlotinib—EGFR—lymph node—breast cancer	0.000149	0.00409	CbGeAlD
Erlotinib—MAP2K5—female gonad—breast cancer	0.000148	0.00407	CbGeAlD
Erlotinib—UGT1A1—endocrine gland—breast cancer	0.000146	0.004	CbGeAlD
Erlotinib—Vandetanib—VEGFA—breast cancer	0.000145	0.06	CrCbGaD
Erlotinib—PIP4K2C—lymph node—breast cancer	0.000144	0.00396	CbGeAlD
Erlotinib—SLCO2B1—uterus—breast cancer	0.000141	0.00387	CbGeAlD
Erlotinib—ABL1—uterus—breast cancer	0.00014	0.00384	CbGeAlD
Erlotinib—SLCO2B1—adipose tissue—breast cancer	0.000138	0.00379	CbGeAlD
Erlotinib—MAP2K5—endocrine gland—breast cancer	0.000138	0.00379	CbGeAlD
Erlotinib—ULK3—lymph node—breast cancer	0.000138	0.00378	CbGeAlD
Erlotinib—ABL1—pituitary gland—breast cancer	0.000137	0.00377	CbGeAlD
Erlotinib—ABL1—adipose tissue—breast cancer	0.000137	0.00376	CbGeAlD
Erlotinib—CYP1B1—skin of body—breast cancer	0.000136	0.00374	CbGeAlD
Erlotinib—ORM1—female reproductive system—breast cancer	0.000132	0.00363	CbGeAlD
Erlotinib—MKNK1—lymph node—breast cancer	0.000129	0.00356	CbGeAlD
Erlotinib—SLCO2B1—female reproductive system—breast cancer	0.000127	0.00348	CbGeAlD
Erlotinib—ABL1—female reproductive system—breast cancer	0.000126	0.00345	CbGeAlD
Erlotinib—ORM1—bone marrow—breast cancer	0.000125	0.00343	CbGeAlD
Erlotinib—SLCO2B1—adrenal gland—breast cancer	0.000124	0.0034	CbGeAlD
Erlotinib—Vandetanib—EGFR—breast cancer	0.000123	0.0506	CrCbGaD
Erlotinib—SLK—lymph node—breast cancer	0.000123	0.00337	CbGeAlD
Erlotinib—ABL1—adrenal gland—breast cancer	0.000123	0.00337	CbGeAlD
Erlotinib—ABL1—Daunorubicin—Idarubicin—breast cancer	0.00012	0.0797	CbGdCrCtD
Erlotinib—ABL1—Doxorubicin—Idarubicin—breast cancer	0.00012	0.0797	CbGdCrCtD
Erlotinib—ABL1—Epirubicin—Idarubicin—breast cancer	0.00012	0.0797	CbGdCrCtD
Erlotinib—ABL1—bone marrow—breast cancer	0.000119	0.00326	CbGeAlD
Erlotinib—CYP1B1—uterus—breast cancer	0.000118	0.00325	CbGeAlD
Erlotinib—Gefitinib—EGFR—breast cancer	0.000117	0.0481	CrCbGaD
Erlotinib—CYP1B1—pituitary gland—breast cancer	0.000116	0.00319	CbGeAlD
Erlotinib—CYP1B1—adipose tissue—breast cancer	0.000116	0.00318	CbGeAlD
Erlotinib—SLCO2B1—female gonad—breast cancer	0.000115	0.00317	CbGeAlD
Erlotinib—ABL1—female gonad—breast cancer	0.000114	0.00314	CbGeAlD
Erlotinib—ALB—adrenal gland—breast cancer	0.000113	0.00311	CbGeAlD
Erlotinib—ORM1—endocrine gland—breast cancer	0.000112	0.00307	CbGeAlD
Erlotinib—SLCO2B1—endocrine gland—breast cancer	0.000107	0.00295	CbGeAlD
Erlotinib—STK10—lymph node—breast cancer	0.000107	0.00293	CbGeAlD
Erlotinib—CYP1B1—female reproductive system—breast cancer	0.000106	0.00292	CbGeAlD
Erlotinib—ABL1—endocrine gland—breast cancer	0.000106	0.00292	CbGeAlD
Erlotinib—CYP1B1—adrenal gland—breast cancer	0.000104	0.00285	CbGeAlD
Erlotinib—CYP1A1—epithelium—breast cancer	0.000101	0.00278	CbGeAlD
Erlotinib—CYP2C8—endometrium—breast cancer	9.83e-05	0.0027	CbGeAlD
Erlotinib—CYP1B1—female gonad—breast cancer	9.67e-05	0.00266	CbGeAlD
Erlotinib—CYP1A1—skin of body—breast cancer	9.62e-05	0.00265	CbGeAlD
Erlotinib—ABCG2—endometrium—breast cancer	9.56e-05	0.00263	CbGeAlD
Erlotinib—MAP2K5—lymph node—breast cancer	9.52e-05	0.00262	CbGeAlD
Erlotinib—CYP1B1—endocrine gland—breast cancer	9e-05	0.00247	CbGeAlD
Erlotinib—Vandetanib—ABCG2—breast cancer	8.96e-05	0.037	CrCbGaD
Erlotinib—CYP2C8—pituitary gland—breast cancer	8.89e-05	0.00245	CbGeAlD
Erlotinib—ABCG2—uterus—breast cancer	8.81e-05	0.00242	CbGeAlD
Erlotinib—ABCG2—pituitary gland—breast cancer	8.65e-05	0.00238	CbGeAlD
Erlotinib—ABCG2—adipose tissue—breast cancer	8.61e-05	0.00237	CbGeAlD
Erlotinib—Gefitinib—ABCG2—breast cancer	8.51e-05	0.0351	CrCbGaD
Erlotinib—CYP1A1—uterus—breast cancer	8.36e-05	0.0023	CbGeAlD
Erlotinib—CYP1A1—adipose tissue—breast cancer	8.18e-05	0.00225	CbGeAlD
Erlotinib—CYP2C8—female reproductive system—breast cancer	8.14e-05	0.00224	CbGeAlD
Erlotinib—CYP3A5—adipose tissue—breast cancer	7.99e-05	0.0022	CbGeAlD
Erlotinib—ORM1—lymph node—breast cancer	7.73e-05	0.00213	CbGeAlD
Erlotinib—ABCG2—adrenal gland—breast cancer	7.73e-05	0.00212	CbGeAlD
Erlotinib—CYP1A1—female reproductive system—breast cancer	7.52e-05	0.00207	CbGeAlD
Erlotinib—ABCG2—bone marrow—breast cancer	7.47e-05	0.00206	CbGeAlD
Erlotinib—SLCO2B1—lymph node—breast cancer	7.41e-05	0.00204	CbGeAlD
Erlotinib—ABL1—lymph node—breast cancer	7.34e-05	0.00202	CbGeAlD
Erlotinib—ABCG2—female gonad—breast cancer	7.2e-05	0.00198	CbGeAlD
Erlotinib—CYP2C8—endocrine gland—breast cancer	6.89e-05	0.00189	CbGeAlD
Erlotinib—CYP1A1—female gonad—breast cancer	6.84e-05	0.00188	CbGeAlD
Erlotinib—ALB—lymph node—breast cancer	6.78e-05	0.00186	CbGeAlD
Erlotinib—CYP3A5—female gonad—breast cancer	6.69e-05	0.00184	CbGeAlD
Erlotinib—Gefitinib—CYP1A1—breast cancer	6.67e-05	0.0275	CrCbGaD
Erlotinib—CYP1A2—endocrine gland—breast cancer	6.45e-05	0.00177	CbGeAlD
Erlotinib—ABCB1—embryo—breast cancer	6.44e-05	0.00177	CbGeAlD
Erlotinib—CYP1A1—endocrine gland—breast cancer	6.36e-05	0.00175	CbGeAlD
Erlotinib—CYP1B1—lymph node—breast cancer	6.22e-05	0.00171	CbGeAlD
Erlotinib—CYP3A5—endocrine gland—breast cancer	6.22e-05	0.00171	CbGeAlD
Erlotinib—CYP3A4—female reproductive system—breast cancer	5.51e-05	0.00152	CbGeAlD
Erlotinib—ABL1—Daunorubicin—Epirubicin—breast cancer	5.49e-05	0.0366	CbGdCrCtD
Erlotinib—ABL1—Idarubicin—Epirubicin—breast cancer	5.49e-05	0.0366	CbGdCrCtD
Erlotinib—ABL1—Doxorubicin—Epirubicin—breast cancer	5.49e-05	0.0366	CbGdCrCtD
Erlotinib—CYP2D6—female reproductive system—breast cancer	5.43e-05	0.00149	CbGeAlD
Erlotinib—ABCB1—epithelium—breast cancer	5.26e-05	0.00145	CbGeAlD
Erlotinib—ABL1—Epirubicin—Doxorubicin—breast cancer	5.08e-05	0.0339	CbGdCrCtD
Erlotinib—ABL1—Idarubicin—Doxorubicin—breast cancer	5.08e-05	0.0339	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Doxorubicin—breast cancer	5.08e-05	0.0339	CbGdCrCtD
Erlotinib—Gefitinib—CYP2D6—breast cancer	4.96e-05	0.0205	CrCbGaD
Erlotinib—CYP2D6—female gonad—breast cancer	4.94e-05	0.00136	CbGeAlD
Erlotinib—ABCB1—endometrium—breast cancer	4.71e-05	0.0013	CbGeAlD
Erlotinib—CYP3A4—endocrine gland—breast cancer	4.67e-05	0.00128	CbGeAlD
Erlotinib—ABCG2—lymph node—breast cancer	4.63e-05	0.00127	CbGeAlD
Erlotinib—CYP2D6—endocrine gland—breast cancer	4.59e-05	0.00126	CbGeAlD
Erlotinib—Vandetanib—CYP3A4—breast cancer	4.48e-05	0.0185	CrCbGaD
Erlotinib—CYP1A1—lymph node—breast cancer	4.4e-05	0.00121	CbGeAlD
Erlotinib—ABCB1—uterus—breast cancer	4.34e-05	0.00119	CbGeAlD
Erlotinib—ABCB1—pituitary gland—breast cancer	4.26e-05	0.00117	CbGeAlD
Erlotinib—Gefitinib—CYP3A4—breast cancer	4.26e-05	0.0176	CrCbGaD
Erlotinib—ABCB1—adipose tissue—breast cancer	4.25e-05	0.00117	CbGeAlD
Erlotinib—Vandetanib—ALB—breast cancer	3.91e-05	0.0161	CrCbGaD
Erlotinib—ABCB1—female reproductive system—breast cancer	3.9e-05	0.00107	CbGeAlD
Erlotinib—ABCB1—adrenal gland—breast cancer	3.81e-05	0.00105	CbGeAlD
Erlotinib—Gefitinib—ALB—breast cancer	3.71e-05	0.0153	CrCbGaD
Erlotinib—ABCB1—bone marrow—breast cancer	3.69e-05	0.00101	CbGeAlD
Erlotinib—ABCB1—female gonad—breast cancer	3.55e-05	0.000977	CbGeAlD
Erlotinib—Gefitinib—ABCB1—breast cancer	3.54e-05	0.0146	CrCbGaD
Erlotinib—ABCB1—endocrine gland—breast cancer	3.3e-05	0.000908	CbGeAlD
Erlotinib—ABCB1—lymph node—breast cancer	2.28e-05	0.000628	CbGeAlD
Erlotinib—Infection—Docetaxel—breast cancer	1.66e-05	0.000182	CcSEcCtD
Erlotinib—Weight decreased—Doxorubicin—breast cancer	1.66e-05	0.000182	CcSEcCtD
Erlotinib—Diarrhoea—Mitoxantrone—breast cancer	1.66e-05	0.000181	CcSEcCtD
Erlotinib—Diarrhoea—Irinotecan—breast cancer	1.66e-05	0.000181	CcSEcCtD
Erlotinib—Pneumonia—Doxorubicin—breast cancer	1.65e-05	0.00018	CcSEcCtD
Erlotinib—Shock—Docetaxel—breast cancer	1.65e-05	0.00018	CcSEcCtD
Erlotinib—Nervous system disorder—Docetaxel—breast cancer	1.64e-05	0.00018	CcSEcCtD
Erlotinib—Pruritus—Fluorouracil—breast cancer	1.64e-05	0.00018	CcSEcCtD
Erlotinib—Thrombocytopenia—Docetaxel—breast cancer	1.64e-05	0.000179	CcSEcCtD
Erlotinib—Infestation NOS—Doxorubicin—breast cancer	1.64e-05	0.000179	CcSEcCtD
Erlotinib—Infestation—Doxorubicin—breast cancer	1.64e-05	0.000179	CcSEcCtD
Erlotinib—Skin disorder—Docetaxel—breast cancer	1.63e-05	0.000178	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Doxorubicin—breast cancer	1.62e-05	0.000178	CcSEcCtD
Erlotinib—Oedema—Capecitabine—breast cancer	1.62e-05	0.000177	CcSEcCtD
Erlotinib—Gastrointestinal pain—Paclitaxel—breast cancer	1.62e-05	0.000177	CcSEcCtD
Erlotinib—Diarrhoea—Gemcitabine—breast cancer	1.61e-05	0.000177	CcSEcCtD
Erlotinib—Renal failure—Doxorubicin—breast cancer	1.61e-05	0.000176	CcSEcCtD
Erlotinib—Infection—Capecitabine—breast cancer	1.61e-05	0.000176	CcSEcCtD
Erlotinib—Erythema multiforme—Methotrexate—breast cancer	1.61e-05	0.000176	CcSEcCtD
Erlotinib—Neuropathy peripheral—Doxorubicin—breast cancer	1.61e-05	0.000176	CcSEcCtD
Erlotinib—Dizziness—Irinotecan—breast cancer	1.6e-05	0.000175	CcSEcCtD
Erlotinib—Haemoglobin—Epirubicin—breast cancer	1.6e-05	0.000175	CcSEcCtD
Erlotinib—Stomatitis—Doxorubicin—breast cancer	1.6e-05	0.000175	CcSEcCtD
Erlotinib—Anorexia—Docetaxel—breast cancer	1.6e-05	0.000175	CcSEcCtD
Erlotinib—Shock—Capecitabine—breast cancer	1.6e-05	0.000175	CcSEcCtD
Erlotinib—Conjunctivitis—Doxorubicin—breast cancer	1.59e-05	0.000174	CcSEcCtD
Erlotinib—Nervous system disorder—Capecitabine—breast cancer	1.59e-05	0.000174	CcSEcCtD
Erlotinib—Haemorrhage—Epirubicin—breast cancer	1.59e-05	0.000174	CcSEcCtD
Erlotinib—Hepatitis—Epirubicin—breast cancer	1.59e-05	0.000174	CcSEcCtD
Erlotinib—Eye disorder—Methotrexate—breast cancer	1.59e-05	0.000174	CcSEcCtD
Erlotinib—Diarrhoea—Fluorouracil—breast cancer	1.59e-05	0.000174	CcSEcCtD
Erlotinib—Thrombocytopenia—Capecitabine—breast cancer	1.59e-05	0.000174	CcSEcCtD
Erlotinib—Skin disorder—Capecitabine—breast cancer	1.57e-05	0.000172	CcSEcCtD
Erlotinib—Urinary tract disorder—Epirubicin—breast cancer	1.57e-05	0.000172	CcSEcCtD
Erlotinib—Connective tissue disorder—Epirubicin—breast cancer	1.56e-05	0.000171	CcSEcCtD
Erlotinib—Abdominal pain—Paclitaxel—breast cancer	1.56e-05	0.000171	CcSEcCtD
Erlotinib—Body temperature increased—Paclitaxel—breast cancer	1.56e-05	0.000171	CcSEcCtD
Erlotinib—Urethral disorder—Epirubicin—breast cancer	1.56e-05	0.000171	CcSEcCtD
Erlotinib—Hepatobiliary disease—Doxorubicin—breast cancer	1.55e-05	0.00017	CcSEcCtD
Erlotinib—Epistaxis—Doxorubicin—breast cancer	1.55e-05	0.000169	CcSEcCtD
Erlotinib—Anorexia—Capecitabine—breast cancer	1.55e-05	0.000169	CcSEcCtD
Erlotinib—Vomiting—Mitoxantrone—breast cancer	1.54e-05	0.000169	CcSEcCtD
Erlotinib—Vomiting—Irinotecan—breast cancer	1.54e-05	0.000169	CcSEcCtD
Erlotinib—Dizziness—Fluorouracil—breast cancer	1.53e-05	0.000168	CcSEcCtD
Erlotinib—Mediastinal disorder—Methotrexate—breast cancer	1.53e-05	0.000168	CcSEcCtD
Erlotinib—Rash—Irinotecan—breast cancer	1.53e-05	0.000167	CcSEcCtD
Erlotinib—Rash—Mitoxantrone—breast cancer	1.53e-05	0.000167	CcSEcCtD
Erlotinib—Dermatitis—Irinotecan—breast cancer	1.53e-05	0.000167	CcSEcCtD
Erlotinib—Dermatitis—Mitoxantrone—breast cancer	1.53e-05	0.000167	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Docetaxel—breast cancer	1.53e-05	0.000167	CcSEcCtD
Erlotinib—Chills—Methotrexate—breast cancer	1.52e-05	0.000167	CcSEcCtD
Erlotinib—Headache—Irinotecan—breast cancer	1.52e-05	0.000166	CcSEcCtD
Erlotinib—Headache—Mitoxantrone—breast cancer	1.52e-05	0.000166	CcSEcCtD
Erlotinib—Insomnia—Docetaxel—breast cancer	1.51e-05	0.000166	CcSEcCtD
Erlotinib—Erythema multiforme—Epirubicin—breast cancer	1.5e-05	0.000164	CcSEcCtD
Erlotinib—Alopecia—Methotrexate—breast cancer	1.5e-05	0.000164	CcSEcCtD
Erlotinib—Vomiting—Gemcitabine—breast cancer	1.5e-05	0.000164	CcSEcCtD
Erlotinib—Dyspnoea—Docetaxel—breast cancer	1.49e-05	0.000163	CcSEcCtD
Erlotinib—Mental disorder—Methotrexate—breast cancer	1.49e-05	0.000163	CcSEcCtD
Erlotinib—Rash—Gemcitabine—breast cancer	1.49e-05	0.000163	CcSEcCtD
Erlotinib—Dermatitis—Gemcitabine—breast cancer	1.49e-05	0.000163	CcSEcCtD
Erlotinib—Eye disorder—Epirubicin—breast cancer	1.49e-05	0.000163	CcSEcCtD
Erlotinib—Erythema—Methotrexate—breast cancer	1.48e-05	0.000162	CcSEcCtD
Erlotinib—Malnutrition—Methotrexate—breast cancer	1.48e-05	0.000162	CcSEcCtD
Erlotinib—Haemoglobin—Doxorubicin—breast cancer	1.48e-05	0.000162	CcSEcCtD
Erlotinib—Headache—Gemcitabine—breast cancer	1.48e-05	0.000162	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Capecitabine—breast cancer	1.48e-05	0.000162	CcSEcCtD
Erlotinib—Vomiting—Fluorouracil—breast cancer	1.48e-05	0.000161	CcSEcCtD
Erlotinib—Dyspepsia—Docetaxel—breast cancer	1.47e-05	0.000161	CcSEcCtD
Erlotinib—Haemorrhage—Doxorubicin—breast cancer	1.47e-05	0.000161	CcSEcCtD
Erlotinib—Hepatitis—Doxorubicin—breast cancer	1.47e-05	0.000161	CcSEcCtD
Erlotinib—Insomnia—Capecitabine—breast cancer	1.47e-05	0.00016	CcSEcCtD
Erlotinib—Rash—Fluorouracil—breast cancer	1.46e-05	0.00016	CcSEcCtD
Erlotinib—Dermatitis—Fluorouracil—breast cancer	1.46e-05	0.00016	CcSEcCtD
Erlotinib—Decreased appetite—Docetaxel—breast cancer	1.46e-05	0.000159	CcSEcCtD
Erlotinib—Headache—Fluorouracil—breast cancer	1.45e-05	0.000159	CcSEcCtD
Erlotinib—Urinary tract disorder—Doxorubicin—breast cancer	1.45e-05	0.000159	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Docetaxel—breast cancer	1.45e-05	0.000158	CcSEcCtD
Erlotinib—Connective tissue disorder—Doxorubicin—breast cancer	1.45e-05	0.000158	CcSEcCtD
Erlotinib—Dyspnoea—Capecitabine—breast cancer	1.45e-05	0.000158	CcSEcCtD
Erlotinib—Fatigue—Docetaxel—breast cancer	1.44e-05	0.000158	CcSEcCtD
Erlotinib—Urethral disorder—Doxorubicin—breast cancer	1.44e-05	0.000158	CcSEcCtD
Erlotinib—Nausea—Irinotecan—breast cancer	1.44e-05	0.000157	CcSEcCtD
Erlotinib—Nausea—Mitoxantrone—breast cancer	1.44e-05	0.000157	CcSEcCtD
Erlotinib—Mediastinal disorder—Epirubicin—breast cancer	1.43e-05	0.000157	CcSEcCtD
Erlotinib—Pain—Docetaxel—breast cancer	1.43e-05	0.000157	CcSEcCtD
Erlotinib—Constipation—Docetaxel—breast cancer	1.43e-05	0.000157	CcSEcCtD
Erlotinib—Back pain—Methotrexate—breast cancer	1.43e-05	0.000157	CcSEcCtD
Erlotinib—Dyspepsia—Capecitabine—breast cancer	1.43e-05	0.000156	CcSEcCtD
Erlotinib—Chills—Epirubicin—breast cancer	1.43e-05	0.000156	CcSEcCtD
Erlotinib—Arrhythmia—Epirubicin—breast cancer	1.42e-05	0.000155	CcSEcCtD
Erlotinib—Asthenia—Paclitaxel—breast cancer	1.42e-05	0.000155	CcSEcCtD
Erlotinib—Decreased appetite—Capecitabine—breast cancer	1.41e-05	0.000154	CcSEcCtD
Erlotinib—Alopecia—Epirubicin—breast cancer	1.4e-05	0.000154	CcSEcCtD
Erlotinib—Nausea—Gemcitabine—breast cancer	1.4e-05	0.000153	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Capecitabine—breast cancer	1.4e-05	0.000153	CcSEcCtD
Erlotinib—Fatigue—Capecitabine—breast cancer	1.4e-05	0.000153	CcSEcCtD
Erlotinib—Pruritus—Paclitaxel—breast cancer	1.4e-05	0.000153	CcSEcCtD
Erlotinib—Mental disorder—Epirubicin—breast cancer	1.39e-05	0.000152	CcSEcCtD
Erlotinib—Erythema multiforme—Doxorubicin—breast cancer	1.39e-05	0.000152	CcSEcCtD
Erlotinib—Pain—Capecitabine—breast cancer	1.39e-05	0.000152	CcSEcCtD
Erlotinib—Constipation—Capecitabine—breast cancer	1.39e-05	0.000152	CcSEcCtD
Erlotinib—Malnutrition—Epirubicin—breast cancer	1.38e-05	0.000151	CcSEcCtD
Erlotinib—Erythema—Epirubicin—breast cancer	1.38e-05	0.000151	CcSEcCtD
Erlotinib—Nausea—Fluorouracil—breast cancer	1.38e-05	0.000151	CcSEcCtD
Erlotinib—Eye disorder—Doxorubicin—breast cancer	1.37e-05	0.00015	CcSEcCtD
Erlotinib—Gastrointestinal pain—Docetaxel—breast cancer	1.37e-05	0.00015	CcSEcCtD
Erlotinib—Flatulence—Epirubicin—breast cancer	1.36e-05	0.000149	CcSEcCtD
Erlotinib—Diarrhoea—Paclitaxel—breast cancer	1.35e-05	0.000148	CcSEcCtD
Erlotinib—Back pain—Epirubicin—breast cancer	1.34e-05	0.000146	CcSEcCtD
Erlotinib—Gastrointestinal pain—Capecitabine—breast cancer	1.33e-05	0.000145	CcSEcCtD
Erlotinib—Mediastinal disorder—Doxorubicin—breast cancer	1.33e-05	0.000145	CcSEcCtD
Erlotinib—Abdominal pain—Docetaxel—breast cancer	1.32e-05	0.000145	CcSEcCtD
Erlotinib—Body temperature increased—Docetaxel—breast cancer	1.32e-05	0.000145	CcSEcCtD
Erlotinib—Chills—Doxorubicin—breast cancer	1.32e-05	0.000144	CcSEcCtD
Erlotinib—Arrhythmia—Doxorubicin—breast cancer	1.31e-05	0.000144	CcSEcCtD
Erlotinib—Dizziness—Paclitaxel—breast cancer	1.31e-05	0.000143	CcSEcCtD
Erlotinib—Alopecia—Doxorubicin—breast cancer	1.3e-05	0.000142	CcSEcCtD
Erlotinib—Cough—Methotrexate—breast cancer	1.29e-05	0.000141	CcSEcCtD
Erlotinib—Mental disorder—Doxorubicin—breast cancer	1.29e-05	0.000141	CcSEcCtD
Erlotinib—Abdominal pain—Capecitabine—breast cancer	1.28e-05	0.00014	CcSEcCtD
Erlotinib—Body temperature increased—Capecitabine—breast cancer	1.28e-05	0.00014	CcSEcCtD
Erlotinib—Erythema—Doxorubicin—breast cancer	1.28e-05	0.00014	CcSEcCtD
Erlotinib—Malnutrition—Doxorubicin—breast cancer	1.28e-05	0.00014	CcSEcCtD
Erlotinib—Flatulence—Doxorubicin—breast cancer	1.26e-05	0.000138	CcSEcCtD
Erlotinib—Arthralgia—Methotrexate—breast cancer	1.26e-05	0.000138	CcSEcCtD
Erlotinib—Chest pain—Methotrexate—breast cancer	1.26e-05	0.000138	CcSEcCtD
Erlotinib—Myalgia—Methotrexate—breast cancer	1.26e-05	0.000138	CcSEcCtD
Erlotinib—Vomiting—Paclitaxel—breast cancer	1.26e-05	0.000137	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.25e-05	0.000137	CcSEcCtD
Erlotinib—Rash—Paclitaxel—breast cancer	1.25e-05	0.000136	CcSEcCtD
Erlotinib—Dermatitis—Paclitaxel—breast cancer	1.24e-05	0.000136	CcSEcCtD
Erlotinib—Syncope—Epirubicin—breast cancer	1.24e-05	0.000136	CcSEcCtD
Erlotinib—Back pain—Doxorubicin—breast cancer	1.24e-05	0.000136	CcSEcCtD
Erlotinib—Headache—Paclitaxel—breast cancer	1.24e-05	0.000135	CcSEcCtD
Erlotinib—Loss of consciousness—Epirubicin—breast cancer	1.22e-05	0.000133	CcSEcCtD
Erlotinib—Cough—Epirubicin—breast cancer	1.21e-05	0.000132	CcSEcCtD
Erlotinib—Asthenia—Docetaxel—breast cancer	1.2e-05	0.000131	CcSEcCtD
Erlotinib—Infection—Methotrexate—breast cancer	1.2e-05	0.000131	CcSEcCtD
Erlotinib—Pruritus—Docetaxel—breast cancer	1.18e-05	0.00013	CcSEcCtD
Erlotinib—Nervous system disorder—Methotrexate—breast cancer	1.18e-05	0.00013	CcSEcCtD
Erlotinib—Thrombocytopenia—Methotrexate—breast cancer	1.18e-05	0.000129	CcSEcCtD
Erlotinib—Arthralgia—Epirubicin—breast cancer	1.18e-05	0.000129	CcSEcCtD
Erlotinib—Chest pain—Epirubicin—breast cancer	1.18e-05	0.000129	CcSEcCtD
Erlotinib—Myalgia—Epirubicin—breast cancer	1.18e-05	0.000129	CcSEcCtD
Erlotinib—Anxiety—Epirubicin—breast cancer	1.17e-05	0.000128	CcSEcCtD
Erlotinib—Nausea—Paclitaxel—breast cancer	1.17e-05	0.000128	CcSEcCtD
Erlotinib—Skin disorder—Methotrexate—breast cancer	1.17e-05	0.000128	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.17e-05	0.000128	CcSEcCtD
Erlotinib—Asthenia—Capecitabine—breast cancer	1.16e-05	0.000127	CcSEcCtD
Erlotinib—Anorexia—Methotrexate—breast cancer	1.15e-05	0.000126	CcSEcCtD
Erlotinib—Syncope—Doxorubicin—breast cancer	1.15e-05	0.000126	CcSEcCtD
Erlotinib—Pruritus—Capecitabine—breast cancer	1.15e-05	0.000126	CcSEcCtD
Erlotinib—Diarrhoea—Docetaxel—breast cancer	1.15e-05	0.000125	CcSEcCtD
Erlotinib—Oedema—Epirubicin—breast cancer	1.13e-05	0.000124	CcSEcCtD
Erlotinib—Loss of consciousness—Doxorubicin—breast cancer	1.13e-05	0.000123	CcSEcCtD
Erlotinib—Infection—Epirubicin—breast cancer	1.12e-05	0.000123	CcSEcCtD
Erlotinib—Cough—Doxorubicin—breast cancer	1.12e-05	0.000122	CcSEcCtD
Erlotinib—Shock—Epirubicin—breast cancer	1.11e-05	0.000122	CcSEcCtD
Erlotinib—Diarrhoea—Capecitabine—breast cancer	1.11e-05	0.000121	CcSEcCtD
Erlotinib—Nervous system disorder—Epirubicin—breast cancer	1.11e-05	0.000121	CcSEcCtD
Erlotinib—Dizziness—Docetaxel—breast cancer	1.11e-05	0.000121	CcSEcCtD
Erlotinib—Thrombocytopenia—Epirubicin—breast cancer	1.11e-05	0.000121	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Methotrexate—breast cancer	1.1e-05	0.00012	CcSEcCtD
Erlotinib—Skin disorder—Epirubicin—breast cancer	1.1e-05	0.00012	CcSEcCtD
Erlotinib—Insomnia—Methotrexate—breast cancer	1.09e-05	0.000119	CcSEcCtD
Erlotinib—Chest pain—Doxorubicin—breast cancer	1.09e-05	0.000119	CcSEcCtD
Erlotinib—Myalgia—Doxorubicin—breast cancer	1.09e-05	0.000119	CcSEcCtD
Erlotinib—Arthralgia—Doxorubicin—breast cancer	1.09e-05	0.000119	CcSEcCtD
Erlotinib—Anxiety—Doxorubicin—breast cancer	1.09e-05	0.000119	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.08e-05	0.000118	CcSEcCtD
Erlotinib—Anorexia—Epirubicin—breast cancer	1.08e-05	0.000118	CcSEcCtD
Erlotinib—Dyspnoea—Methotrexate—breast cancer	1.08e-05	0.000118	CcSEcCtD
Erlotinib—Dizziness—Capecitabine—breast cancer	1.07e-05	0.000117	CcSEcCtD
Erlotinib—Vomiting—Docetaxel—breast cancer	1.06e-05	0.000116	CcSEcCtD
Erlotinib—Dyspepsia—Methotrexate—breast cancer	1.06e-05	0.000116	CcSEcCtD
Erlotinib—Rash—Docetaxel—breast cancer	1.06e-05	0.000116	CcSEcCtD
Erlotinib—Dermatitis—Docetaxel—breast cancer	1.05e-05	0.000115	CcSEcCtD
Erlotinib—Decreased appetite—Methotrexate—breast cancer	1.05e-05	0.000115	CcSEcCtD
Erlotinib—Headache—Docetaxel—breast cancer	1.05e-05	0.000115	CcSEcCtD
Erlotinib—Oedema—Doxorubicin—breast cancer	1.05e-05	0.000114	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Methotrexate—breast cancer	1.04e-05	0.000114	CcSEcCtD
Erlotinib—Fatigue—Methotrexate—breast cancer	1.04e-05	0.000114	CcSEcCtD
Erlotinib—Infection—Doxorubicin—breast cancer	1.04e-05	0.000114	CcSEcCtD
Erlotinib—Pain—Methotrexate—breast cancer	1.03e-05	0.000113	CcSEcCtD
Erlotinib—Vomiting—Capecitabine—breast cancer	1.03e-05	0.000113	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Epirubicin—breast cancer	1.03e-05	0.000113	CcSEcCtD
Erlotinib—Shock—Doxorubicin—breast cancer	1.03e-05	0.000113	CcSEcCtD
Erlotinib—Nervous system disorder—Doxorubicin—breast cancer	1.02e-05	0.000112	CcSEcCtD
Erlotinib—Thrombocytopenia—Doxorubicin—breast cancer	1.02e-05	0.000112	CcSEcCtD
Erlotinib—Rash—Capecitabine—breast cancer	1.02e-05	0.000112	CcSEcCtD
Erlotinib—Insomnia—Epirubicin—breast cancer	1.02e-05	0.000112	CcSEcCtD
Erlotinib—Dermatitis—Capecitabine—breast cancer	1.02e-05	0.000112	CcSEcCtD
Erlotinib—Headache—Capecitabine—breast cancer	1.02e-05	0.000111	CcSEcCtD
Erlotinib—Skin disorder—Doxorubicin—breast cancer	1.02e-05	0.000111	CcSEcCtD
Erlotinib—Dyspnoea—Epirubicin—breast cancer	1.01e-05	0.00011	CcSEcCtD
Erlotinib—Anorexia—Doxorubicin—breast cancer	9.96e-06	0.000109	CcSEcCtD
Erlotinib—Nausea—Docetaxel—breast cancer	9.95e-06	0.000109	CcSEcCtD
Erlotinib—Dyspepsia—Epirubicin—breast cancer	9.94e-06	0.000109	CcSEcCtD
Erlotinib—Gastrointestinal pain—Methotrexate—breast cancer	9.87e-06	0.000108	CcSEcCtD
Erlotinib—Decreased appetite—Epirubicin—breast cancer	9.82e-06	0.000107	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Epirubicin—breast cancer	9.75e-06	0.000107	CcSEcCtD
Erlotinib—Fatigue—Epirubicin—breast cancer	9.74e-06	0.000107	CcSEcCtD
Erlotinib—Pain—Epirubicin—breast cancer	9.66e-06	0.000106	CcSEcCtD
Erlotinib—Constipation—Epirubicin—breast cancer	9.66e-06	0.000106	CcSEcCtD
Erlotinib—Nausea—Capecitabine—breast cancer	9.63e-06	0.000105	CcSEcCtD
Erlotinib—Body temperature increased—Methotrexate—breast cancer	9.54e-06	0.000104	CcSEcCtD
Erlotinib—Abdominal pain—Methotrexate—breast cancer	9.54e-06	0.000104	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Doxorubicin—breast cancer	9.52e-06	0.000104	CcSEcCtD
Erlotinib—Insomnia—Doxorubicin—breast cancer	9.45e-06	0.000103	CcSEcCtD
Erlotinib—Dyspnoea—Doxorubicin—breast cancer	9.32e-06	0.000102	CcSEcCtD
Erlotinib—Gastrointestinal pain—Epirubicin—breast cancer	9.24e-06	0.000101	CcSEcCtD
Erlotinib—Dyspepsia—Doxorubicin—breast cancer	9.2e-06	0.000101	CcSEcCtD
Erlotinib—Decreased appetite—Doxorubicin—breast cancer	9.09e-06	9.94e-05	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Doxorubicin—breast cancer	9.02e-06	9.87e-05	CcSEcCtD
Erlotinib—Fatigue—Doxorubicin—breast cancer	9.01e-06	9.86e-05	CcSEcCtD
Erlotinib—Pain—Doxorubicin—breast cancer	8.94e-06	9.78e-05	CcSEcCtD
Erlotinib—Constipation—Doxorubicin—breast cancer	8.94e-06	9.78e-05	CcSEcCtD
Erlotinib—Abdominal pain—Epirubicin—breast cancer	8.93e-06	9.77e-05	CcSEcCtD
Erlotinib—Body temperature increased—Epirubicin—breast cancer	8.93e-06	9.77e-05	CcSEcCtD
Erlotinib—Asthenia—Methotrexate—breast cancer	8.66e-06	9.47e-05	CcSEcCtD
Erlotinib—Gastrointestinal pain—Doxorubicin—breast cancer	8.55e-06	9.35e-05	CcSEcCtD
Erlotinib—Pruritus—Methotrexate—breast cancer	8.54e-06	9.34e-05	CcSEcCtD
Erlotinib—Abdominal pain—Doxorubicin—breast cancer	8.26e-06	9.04e-05	CcSEcCtD
Erlotinib—Body temperature increased—Doxorubicin—breast cancer	8.26e-06	9.04e-05	CcSEcCtD
Erlotinib—Diarrhoea—Methotrexate—breast cancer	8.26e-06	9.04e-05	CcSEcCtD
Erlotinib—Asthenia—Epirubicin—breast cancer	8.1e-06	8.87e-05	CcSEcCtD
Erlotinib—Pruritus—Epirubicin—breast cancer	7.99e-06	8.74e-05	CcSEcCtD
Erlotinib—Dizziness—Methotrexate—breast cancer	7.98e-06	8.73e-05	CcSEcCtD
Erlotinib—Diarrhoea—Epirubicin—breast cancer	7.73e-06	8.46e-05	CcSEcCtD
Erlotinib—Vomiting—Methotrexate—breast cancer	7.67e-06	8.4e-05	CcSEcCtD
Erlotinib—Rash—Methotrexate—breast cancer	7.61e-06	8.33e-05	CcSEcCtD
Erlotinib—Dermatitis—Methotrexate—breast cancer	7.6e-06	8.32e-05	CcSEcCtD
Erlotinib—Headache—Methotrexate—breast cancer	7.56e-06	8.27e-05	CcSEcCtD
Erlotinib—Asthenia—Doxorubicin—breast cancer	7.5e-06	8.2e-05	CcSEcCtD
Erlotinib—Dizziness—Epirubicin—breast cancer	7.47e-06	8.17e-05	CcSEcCtD
Erlotinib—Pruritus—Doxorubicin—breast cancer	7.39e-06	8.09e-05	CcSEcCtD
Erlotinib—Vomiting—Epirubicin—breast cancer	7.18e-06	7.86e-05	CcSEcCtD
Erlotinib—Nausea—Methotrexate—breast cancer	7.17e-06	7.84e-05	CcSEcCtD
Erlotinib—Diarrhoea—Doxorubicin—breast cancer	7.15e-06	7.82e-05	CcSEcCtD
Erlotinib—Rash—Epirubicin—breast cancer	7.12e-06	7.79e-05	CcSEcCtD
Erlotinib—Dermatitis—Epirubicin—breast cancer	7.12e-06	7.78e-05	CcSEcCtD
Erlotinib—Headache—Epirubicin—breast cancer	7.08e-06	7.74e-05	CcSEcCtD
Erlotinib—Dizziness—Doxorubicin—breast cancer	6.91e-06	7.56e-05	CcSEcCtD
Erlotinib—Nausea—Epirubicin—breast cancer	6.71e-06	7.34e-05	CcSEcCtD
Erlotinib—Vomiting—Doxorubicin—breast cancer	6.65e-06	7.27e-05	CcSEcCtD
Erlotinib—Rash—Doxorubicin—breast cancer	6.59e-06	7.21e-05	CcSEcCtD
Erlotinib—Dermatitis—Doxorubicin—breast cancer	6.58e-06	7.2e-05	CcSEcCtD
Erlotinib—Headache—Doxorubicin—breast cancer	6.55e-06	7.16e-05	CcSEcCtD
Erlotinib—Nausea—Doxorubicin—breast cancer	6.21e-06	6.79e-05	CcSEcCtD
Erlotinib—CYP2C8—Metabolism—ERCC2—breast cancer	5.21e-07	7.15e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—SRC—breast cancer	5.21e-07	7.15e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC5A5—breast cancer	5.21e-07	7.15e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALDOA—breast cancer	5.2e-07	7.14e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAPK3—breast cancer	5.2e-07	7.13e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—HMOX1—breast cancer	5.18e-07	7.11e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ERCC2—breast cancer	5.18e-07	7.11e-06	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKT1—breast cancer	5.18e-07	7.11e-06	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTEN—breast cancer	5.18e-07	7.1e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PIK3CA—breast cancer	5.17e-07	7.1e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ITPR1—breast cancer	5.17e-07	7.1e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SERPINE1—breast cancer	5.17e-07	7.09e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KRAS—breast cancer	5.13e-07	7.04e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KRAS—breast cancer	5.11e-07	7.02e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CB—breast cancer	5.08e-07	6.97e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NCOA3—breast cancer	5.05e-07	6.93e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—breast cancer	5.04e-07	6.91e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NQO1—breast cancer	5.03e-07	6.9e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC2A1—breast cancer	5.03e-07	6.9e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—STAT3—breast cancer	5.03e-07	6.89e-06	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PIK3CA—breast cancer	5.02e-07	6.89e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC2A2—breast cancer	5.01e-07	6.88e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—breast cancer	5e-07	6.87e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—COMT—breast cancer	4.98e-07	6.83e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTP1—breast cancer	4.95e-07	6.8e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NOS3—breast cancer	4.93e-07	6.77e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CAV1—breast cancer	4.93e-07	6.76e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	4.93e-07	6.76e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTR—breast cancer	4.91e-07	6.74e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ABCG2—breast cancer	4.91e-07	6.74e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CPT1A—breast cancer	4.91e-07	6.74e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP3A4—breast cancer	4.91e-07	6.73e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MTHFR—breast cancer	4.9e-07	6.72e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TYMS—breast cancer	4.89e-07	6.7e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—HMOX1—breast cancer	4.89e-07	6.7e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	4.88e-07	6.7e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ITPR1—breast cancer	4.87e-07	6.69e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MTHFR—breast cancer	4.87e-07	6.68e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PLA2G4A—breast cancer	4.83e-07	6.63e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTM1—breast cancer	4.83e-07	6.63e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NCOR1—breast cancer	4.83e-07	6.63e-06	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTEN—breast cancer	4.83e-07	6.62e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP1B1—breast cancer	4.82e-07	6.62e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HPGDS—breast cancer	4.82e-07	6.61e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—MAPK3—breast cancer	4.8e-07	6.59e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HBA1—breast cancer	4.79e-07	6.57e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—breast cancer	4.79e-07	6.57e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CG—breast cancer	4.75e-07	6.52e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HSP90AA1—breast cancer	4.73e-07	6.49e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PIK3CA—breast cancer	4.72e-07	6.47e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	4.71e-07	6.46e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PIK3CA—breast cancer	4.7e-07	6.45e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ABCB1—breast cancer	4.69e-07	6.43e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MDM2—breast cancer	4.68e-07	6.42e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KRAS—breast cancer	4.67e-07	6.41e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTT1—breast cancer	4.67e-07	6.41e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ACHE—breast cancer	4.67e-07	6.41e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—breast cancer	4.67e-07	6.41e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RAF1—breast cancer	4.66e-07	6.4e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—TGFB1—breast cancer	4.66e-07	6.39e-06	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—breast cancer	4.65e-07	6.38e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RELA—breast cancer	4.64e-07	6.37e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GPX1—breast cancer	4.63e-07	6.35e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ERBB2—breast cancer	4.61e-07	6.33e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TYMS—breast cancer	4.61e-07	6.32e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NCOA1—breast cancer	4.6e-07	6.31e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—breast cancer	4.58e-07	6.28e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP1A1—breast cancer	4.58e-07	6.28e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—breast cancer	4.56e-07	6.26e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MTOR—breast cancer	4.55e-07	6.25e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CB—breast cancer	4.55e-07	6.25e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PLA2G4A—breast cancer	4.55e-07	6.25e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NCOR1—breast cancer	4.55e-07	6.25e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTM1—breast cancer	4.55e-07	6.25e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ERCC2—breast cancer	4.54e-07	6.23e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—STK11—breast cancer	4.54e-07	6.22e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP19A1—breast cancer	4.54e-07	6.22e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CAV1—breast cancer	4.52e-07	6.2e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CAV1—breast cancer	4.49e-07	6.17e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CG—breast cancer	4.49e-07	6.16e-06	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—breast cancer	4.45e-07	6.1e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP17A1—breast cancer	4.42e-07	6.07e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTEN—breast cancer	4.39e-07	6.03e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS1—breast cancer	4.38e-07	6.01e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ENO1—breast cancer	4.38e-07	6.01e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCL8—breast cancer	4.38e-07	6e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—breast cancer	4.36e-07	5.99e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GPX1—breast cancer	4.36e-07	5.98e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—breast cancer	4.35e-07	5.96e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	4.32e-07	5.92e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP1A1—breast cancer	4.32e-07	5.92e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—KRAS—breast cancer	4.31e-07	5.92e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	4.29e-07	5.89e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP2D6—breast cancer	4.29e-07	5.89e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PIK3CA—breast cancer	4.29e-07	5.89e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ERCC2—breast cancer	4.28e-07	5.87e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN1B—breast cancer	4.27e-07	5.86e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MTHFR—breast cancer	4.27e-07	5.86e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	4.26e-07	5.84e-06	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT1—breast cancer	4.23e-07	5.8e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—COMT—breast cancer	4.22e-07	5.78e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NCOA2—breast cancer	4.21e-07	5.78e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTP1—breast cancer	4.2e-07	5.76e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CASP3—breast cancer	4.19e-07	5.75e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL2—breast cancer	4.18e-07	5.74e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CD—breast cancer	4.18e-07	5.73e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—breast cancer	4.16e-07	5.71e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HMOX1—breast cancer	4.14e-07	5.68e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ITPR1—breast cancer	4.13e-07	5.67e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ALB—breast cancer	4.13e-07	5.66e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CG—breast cancer	4.12e-07	5.65e-06	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT1—breast cancer	4.1e-07	5.63e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CG—breast cancer	4.09e-07	5.62e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—FASN—breast cancer	4.09e-07	5.61e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCND1—breast cancer	4.08e-07	5.59e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—BCHE—breast cancer	4.07e-07	5.58e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—JUN—breast cancer	4.07e-07	5.58e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CTNNB1—breast cancer	4.04e-07	5.54e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MTHFR—breast cancer	4.02e-07	5.52e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC5A5—breast cancer	4.02e-07	5.52e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ABCB1—breast cancer	3.97e-07	5.45e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—breast cancer	3.97e-07	5.45e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CA—breast cancer	3.96e-07	5.44e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—breast cancer	3.96e-07	5.43e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CD—breast cancer	3.95e-07	5.42e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NOS3—breast cancer	3.95e-07	5.41e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN1A—breast cancer	3.94e-07	5.41e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CAV1—breast cancer	3.94e-07	5.4e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTEN—breast cancer	3.93e-07	5.4e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TYMS—breast cancer	3.9e-07	5.35e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ALB—breast cancer	3.9e-07	5.35e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC2A1—breast cancer	3.88e-07	5.33e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NQO1—breast cancer	3.88e-07	5.33e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PLA2G4A—breast cancer	3.86e-07	5.29e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTM1—breast cancer	3.86e-07	5.29e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NCOR1—breast cancer	3.86e-07	5.29e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT1—breast cancer	3.85e-07	5.29e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK8—breast cancer	3.85e-07	5.28e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT1—breast cancer	3.84e-07	5.27e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—breast cancer	3.8e-07	5.22e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NOS3—breast cancer	3.73e-07	5.11e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP1B1—breast cancer	3.72e-07	5.11e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CAV1—breast cancer	3.71e-07	5.09e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GPX1—breast cancer	3.69e-07	5.07e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—breast cancer	3.67e-07	5.03e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP1A1—breast cancer	3.66e-07	5.02e-06	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CA—breast cancer	3.65e-07	5.01e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HSP90AA1—breast cancer	3.65e-07	5.01e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SRC—breast cancer	3.65e-07	5.01e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CB—breast cancer	3.64e-07	5e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ERCC2—breast cancer	3.63e-07	4.97e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CD—breast cancer	3.62e-07	4.97e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—breast cancer	3.61e-07	4.95e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CD—breast cancer	3.6e-07	4.94e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CG—breast cancer	3.59e-07	4.92e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ALB—breast cancer	3.57e-07	4.9e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—breast cancer	3.55e-07	4.88e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NCOA1—breast cancer	3.55e-07	4.87e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STAT3—breast cancer	3.52e-07	4.83e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—breast cancer	3.51e-07	4.82e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT1—breast cancer	3.51e-07	4.81e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—STK11—breast cancer	3.5e-07	4.8e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP19A1—breast cancer	3.5e-07	4.8e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CB—breast cancer	3.44e-07	4.72e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NOS3—breast cancer	3.42e-07	4.69e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—breast cancer	3.41e-07	4.68e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MTHFR—breast cancer	3.41e-07	4.68e-06	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CA—breast cancer	3.41e-07	4.67e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NOS3—breast cancer	3.4e-07	4.66e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CG—breast cancer	3.38e-07	4.64e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK3—breast cancer	3.36e-07	4.61e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—breast cancer	3.27e-07	4.49e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TGFB1—breast cancer	3.26e-07	4.48e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—COMT—breast cancer	3.25e-07	4.46e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTP1—breast cancer	3.24e-07	4.44e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT1—breast cancer	3.24e-07	4.44e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HMOX1—breast cancer	3.19e-07	4.38e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ITPR1—breast cancer	3.19e-07	4.37e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CB—breast cancer	3.16e-07	4.33e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CD—breast cancer	3.15e-07	4.33e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTEN—breast cancer	3.15e-07	4.32e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CAV1—breast cancer	3.14e-07	4.31e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CB—breast cancer	3.14e-07	4.3e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—breast cancer	3.13e-07	4.29e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ALB—breast cancer	3.11e-07	4.27e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—breast cancer	3.11e-07	4.26e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CA—breast cancer	3.1e-07	4.25e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ABCB1—breast cancer	3.07e-07	4.21e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KRAS—breast cancer	3.02e-07	4.15e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TYMS—breast cancer	3.01e-07	4.13e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	3e-07	4.12e-06	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AKT1—breast cancer	2.98e-07	4.09e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NOS3—breast cancer	2.98e-07	4.09e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PLA2G4A—breast cancer	2.98e-07	4.08e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NCOR1—breast cancer	2.98e-07	4.08e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTM1—breast cancer	2.98e-07	4.08e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTEN—breast cancer	2.97e-07	4.08e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CD—breast cancer	2.97e-07	4.08e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ALB—breast cancer	2.93e-07	4.02e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CG—breast cancer	2.86e-07	3.93e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GPX1—breast cancer	2.85e-07	3.91e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP1A1—breast cancer	2.82e-07	3.87e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NOS3—breast cancer	2.81e-07	3.85e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ERCC2—breast cancer	2.8e-07	3.84e-06	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AKT1—breast cancer	2.78e-07	3.82e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CA—breast cancer	2.78e-07	3.81e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CB—breast cancer	2.75e-07	3.77e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTEN—breast cancer	2.73e-07	3.74e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—breast cancer	2.72e-07	3.74e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTEN—breast cancer	2.71e-07	3.72e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—breast cancer	2.69e-07	3.68e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTHFR—breast cancer	2.63e-07	3.61e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CB—breast cancer	2.59e-07	3.55e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—breast cancer	2.57e-07	3.52e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—breast cancer	2.57e-07	3.52e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AKT1—breast cancer	2.53e-07	3.47e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CD—breast cancer	2.52e-07	3.45e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ALB—breast cancer	2.49e-07	3.41e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—breast cancer	2.46e-07	3.37e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CAV1—breast cancer	2.43e-07	3.33e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NOS3—breast cancer	2.38e-07	3.26e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTEN—breast cancer	2.38e-07	3.26e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT1—breast cancer	2.27e-07	3.11e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTEN—breast cancer	2.24e-07	3.07e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CA—breast cancer	2.22e-07	3.05e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CG—breast cancer	2.21e-07	3.03e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CB—breast cancer	2.19e-07	3.01e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—breast cancer	2.17e-07	2.98e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CA—breast cancer	2.1e-07	2.88e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CD—breast cancer	1.94e-07	2.67e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CA—breast cancer	1.92e-07	2.64e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALB—breast cancer	1.92e-07	2.63e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CA—breast cancer	1.91e-07	2.62e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTEN—breast cancer	1.9e-07	2.6e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NOS3—breast cancer	1.83e-07	2.52e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKT1—breast cancer	1.81e-07	2.49e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKT1—breast cancer	1.71e-07	2.35e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CB—breast cancer	1.69e-07	2.32e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—breast cancer	1.68e-07	2.3e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CA—breast cancer	1.68e-07	2.3e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CA—breast cancer	1.58e-07	2.17e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKT1—breast cancer	1.57e-07	2.16e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKT1—breast cancer	1.56e-07	2.14e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTEN—breast cancer	1.46e-07	2.01e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKT1—breast cancer	1.37e-07	1.88e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CA—breast cancer	1.34e-07	1.84e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKT1—breast cancer	1.29e-07	1.77e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKT1—breast cancer	1.09e-07	1.5e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CA—breast cancer	1.03e-07	1.42e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKT1—breast cancer	8.43e-08	1.16e-06	CbGpPWpGaD
